These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 25791210)

  • 41. Rapid analysis of protein structure and dynamics by hydrogen/deuterium exchange mass spectrometry.
    Hamuro Y; Coales SJ; Southern MR; Nemeth-Cawley JF; Stranz DD; Griffin PR
    J Biomol Tech; 2003 Sep; 14(3):171-82. PubMed ID: 13678147
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Modern mass spectrometry-based structural proteomics.
    Petrotchenko EV; Borchers CH
    Adv Protein Chem Struct Biol; 2014; 95():193-213. PubMed ID: 24985773
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Localizing flexible regions in proteins using hydrogen-deuterium exchange mass spectrometry.
    Bobst CE; Kaltashov IA
    Methods Mol Biol; 2012; 896():375-85. PubMed ID: 22821538
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Advances and challenges in analytical characterization of biotechnology products: mass spectrometry-based approaches to study properties and behavior of protein therapeutics.
    Kaltashov IA; Bobst CE; Abzalimov RR; Wang G; Baykal B; Wang S
    Biotechnol Adv; 2012; 30(1):210-22. PubMed ID: 21619926
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mass spectrometry based tools to investigate protein-ligand interactions for drug discovery.
    Pacholarz KJ; Garlish RA; Taylor RJ; Barran PE
    Chem Soc Rev; 2012 Jun; 41(11):4335-55. PubMed ID: 22532017
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Top-down structural analysis of posttranslationally modified proteins by Fourier transform ion cyclotron resonance-MS with hydrogen/deuterium exchange and electron capture dissociation.
    Pan J; Borchers CH
    Proteomics; 2013 Mar; 13(6):974-81. PubMed ID: 23319428
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mass-spectrometry-based characterization of oxidations in proteins.
    Artemenko K; Mi J; Bergquist J
    Free Radic Res; 2015 May; 49(5):477-93. PubMed ID: 25884782
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Progress in the research of amorphous pharmaceuticals].
    Ying J; Lü Y; Du GH
    Yao Xue Xue Bao; 2009 May; 44(5):443-8. PubMed ID: 19618716
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High throughput screening of protein formulation stability: practical considerations.
    Capelle MA; Gurny R; Arvinte T
    Eur J Pharm Biopharm; 2007 Feb; 65(2):131-48. PubMed ID: 17107777
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Forced degradation and impurity profiling: recent trends in analytical perspectives.
    Jain D; Basniwal PK
    J Pharm Biomed Anal; 2013 Dec; 86():11-35. PubMed ID: 23969330
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The future of drug discovery: enabling technologies for enhancing lead characterization and profiling therapeutic potential.
    Janero DR
    Expert Opin Drug Discov; 2014 Aug; 9(8):847-58. PubMed ID: 24965547
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ranking poses in structure-based lead discovery and optimization: current trends in scoring function development.
    Rajamani R; Good AC
    Curr Opin Drug Discov Devel; 2007 May; 10(3):308-15. PubMed ID: 17554857
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Characterizing short-lived protein folding intermediates by top-down hydrogen exchange mass spectrometry.
    Pan J; Han J; Borchers CH; Konermann L
    Anal Chem; 2010 Oct; 82(20):8591-7. PubMed ID: 20849085
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Affinity capture of biotinylated proteins at acidic conditions to facilitate hydrogen/deuterium exchange mass spectrometry analysis of multimeric protein complexes.
    Jensen PF; Jørgensen TJ; Koefoed K; Nygaard F; Sen JW
    Anal Chem; 2013 Aug; 85(15):7052-9. PubMed ID: 23534402
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dissecting the effect of RNA aptamer binding on the dynamics of plasminogen activator inhibitor 1 using hydrogen/deuterium exchange mass spectrometry.
    Trelle MB; Dupont DM; Madsen JB; Andreasen PA; Jørgensen TJ
    ACS Chem Biol; 2014 Jan; 9(1):174-82. PubMed ID: 24138169
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mass spectrometry combined with oxidative labeling for exploring protein structure and folding.
    Konermann L; Stocks BB; Pan Y; Tong X
    Mass Spectrom Rev; 2010; 29(4):651-67. PubMed ID: 19672951
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Proteins behaving badly: emerging technologies in profiling biopharmaceutical aggregation.
    Hamrang Z; Rattray NJ; Pluen A
    Trends Biotechnol; 2013 Aug; 31(8):448-58. PubMed ID: 23769716
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Critical practical aspects in the application of liquid chromatography-mass spectrometric studies for the characterization of impurities and degradation products.
    Narayanam M; Handa T; Sharma P; Jhajra S; Muthe PK; Dappili PK; Shah RP; Singh S
    J Pharm Biomed Anal; 2014 Jan; 87():191-217. PubMed ID: 23706957
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lead optimization via high-throughput molecular docking.
    Joseph-McCarthy D; Baber JC; Feyfant E; Thompson DC; Humblet C
    Curr Opin Drug Discov Devel; 2007 May; 10(3):264-74. PubMed ID: 17554852
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mass spectrometry-based methods in characterization of the higher order structure of protein therapeutics.
    Kaltashov IA; Bobst CE; Pawlowski J; Wang G
    J Pharm Biomed Anal; 2020 May; 184():113169. PubMed ID: 32092629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.